Atherosclerosis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Atherosclerosis - Pipeline Review, H2 2018’, provides an overview of the Atherosclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atherosclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atherosclerosis

- The report reviews pipeline therapeutics for Atherosclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Atherosclerosis therapeutics and enlists all their major and minor projects

- The report assesses Atherosclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Atherosclerosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Atherosclerosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ache Laboratorios Farmaceuticos SA

AFFiRiS AG

Amgen Inc

Annexin Pharmaceuticals AB

AstraZeneca Plc

Athera Biotechnologies AB

Boehringer Ingelheim GmbH

Cardax Inc

Cerenis Therapeutics Holding SA ...

Ache Laboratorios Farmaceuticos SA

AFFiRiS AG

Amgen Inc

Annexin Pharmaceuticals AB

AstraZeneca Plc

Athera Biotechnologies AB

Boehringer Ingelheim GmbH

Cardax Inc

Cerenis Therapeutics Holding SA

ChemoCentryx Inc

CohBar Inc

Daiichi Sankyo Co Ltd

DoNatur GmbH

Dybly AG

Esperion Therapeutics Inc

GenKyoTex SA

GlaxoSmithKline Plc

Immusoft Corp

Inotrem SA

Inspyr Therapeutics Inc

Iproteos SL

KineMed Inc

Kowa Co Ltd

LG Chem Ltd

LipimetiX Development Inc

MedImmune LLC

NuSirt Biopharma Inc

Omeros Corp

Regeneron Pharmaceuticals Inc

Shin Poong PharmCo Ltd

The Medicines Company

Tolerys SA

Vascular Biogenics Ltd

Vicore Pharma AB

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Atherosclerosis – Overview 6

Atherosclerosis – Therapeutics Development 7

Atherosclerosis – Therapeutics Assessment 21

Atherosclerosis – ...

Table of Contents

Table of Contents 2

Introduction 5

Atherosclerosis – Overview 6

Atherosclerosis – Therapeutics Development 7

Atherosclerosis – Therapeutics Assessment 21

Atherosclerosis – Companies Involved in Therapeutics Development 33

Atherosclerosis – Drug Profiles 50

Atherosclerosis – Dormant Projects 203

Atherosclerosis – Discontinued Products 212

Atherosclerosis – Product Development Milestones 215

Appendix 234

List of Tables

List of Tables

Number of Products under Development for Atherosclerosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Atherosclerosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Atherosclerosis – Pipeline by Ache Laboratorios Farmaceuticos SA, H2 2018

Atherosclerosis – Pipeline by AFFiRiS AG, H2 2018

Atherosclerosis – Pipeline by Amgen Inc, H2 2018

Atherosclerosis – Pipeline by Annexin Pharmaceuticals AB, H2 2018

Atherosclerosis – Pipeline by AstraZeneca Plc, H2 2018

Atherosclerosis – Pipeline by Athera Biotechnologies AB, H2 2018

Atherosclerosis – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Atherosclerosis – Pipeline by Cardax Inc, H2 2018

Atherosclerosis – Pipeline by Cerenis Therapeutics Holding SA, H2 2018

Atherosclerosis – Pipeline by ChemoCentryx Inc, H2 2018

Atherosclerosis – Pipeline by CohBar Inc, H2 2018

Atherosclerosis – Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Atherosclerosis – Pipeline by DoNatur GmbH, H2 2018

Atherosclerosis – Pipeline by Dybly AG, H2 2018

Atherosclerosis – Pipeline by Esperion Therapeutics Inc, H2 2018

Atherosclerosis – Pipeline by GenKyoTex SA, H2 2018

Atherosclerosis – Pipeline by GlaxoSmithKline Plc, H2 2018

Atherosclerosis – Pipeline by Immusoft Corp, H2 2018

Atherosclerosis – Pipeline by Inotrem SA, H2 2018

Atherosclerosis – Pipeline by Inspyr Therapeutics Inc, H2 2018

Atherosclerosis – Pipeline by Iproteos SL, H2 2018

Atherosclerosis – Pipeline by KineMed Inc, H2 2018

Atherosclerosis – Pipeline by Kowa Co Ltd, H2 2018

Atherosclerosis – Pipeline by LG Chem Ltd, H2 2018

Atherosclerosis – Pipeline by LipimetiX Development Inc, H2 2018

Atherosclerosis – Pipeline by MedImmune LLC, H2 2018

Atherosclerosis – Pipeline by NuSirt Biopharma Inc, H2 2018

Atherosclerosis – Pipeline by Omeros Corp, H2 2018

Atherosclerosis – Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Atherosclerosis – Pipeline by Shin Poong PharmCo Ltd, H2 2018

Atherosclerosis – Pipeline by The Medicines Company, H2 2018

Atherosclerosis – Pipeline by Tolerys SA, H2 2018

Atherosclerosis – Pipeline by Vascular Biogenics Ltd, H2 2018

Atherosclerosis – Pipeline by Vicore Pharma AB, H2 2018

Atherosclerosis – Pipeline by XBiotech Inc, H2 2018

Atherosclerosis – Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Atherosclerosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Atherosclerosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports